Derms on Drugs

The Derms on Drugs are joined by Dr. Peter Lio to take a dive into the "root causes" of atopic dermatitis and what we can do to address them.  Maybe you've heard about the "NICE" Axis - the Neuro-Immuno-Cutaneo-Endocrine Axis and thought you were on the cutting edge.  Well, you're not.  The new and updated model is the "SINGE" Network - the Skin-Immuno-Neuro-Gastro-Endocrine Network.  Join us this week to get the answers to more of the questions you didn't know you should have!

New data confirms again that elimination diets don't help with atopic dermatitis and data shows that avoiding foods makes you more likely so how do you talk to patients who are convinced food allergy is driving their atopic dermatitis?
Should you be recommending probiotics to you atopic dermatitis patients (and which one)?
How (and why) do probiotics work for atopic dermatitis?
What does a lion in your basement have to do with atopic dermatitis?
How do you handle patients who say that all moisturizers sting when you put them on?
How do you deal with people in whom Staph aureus is playing a major role in their atopic dermatitis?
What's coming for atopic dermatitis in 2026?

This week's episode will help you not get sued, talk to psoriasis patients about diet, manage transplant patients with skin cancer and more.  Join us again this week to get the answers to burning dermatology questions you didn't know you had.   
Can the Mediterranean diet help with psoriasis?  And why do people get 'gluten sensitivity' from US wheat but not Mediterranean wheat?
When do you recommend changing immunosuppression in transplant patients with skin cancer?
Are people with atopic dermatitis more or less likely to have contact derm than other people?
Hailey Hailey is an awful disease that's hard to treat - can dupilumab help?  What other 'off the beaten path' therapies are there?
Cosibelimab is the new kid on the block for bad squamous cell carcinoma - is it any better than existing treatments?
When do you need to be worried about underlying malignancy in dermatomyositis patients?
Oral minoxidil causes hairy arms in men.  But do they care?
You know Bactrim can cause SJS and TEN, but do you know about the other life threatening side effect that specifically affects young healthy people with acne?

The Derms on Drugs bring in a heavy hitter straight out of silicon valley to talk AI and the future of dermatology.  Dr. Faranak Kamangar is a Board Certified Dermatologist who founded, built and continues to improve DermGPT - a derm specific LLM that just outperformed ChatGPT in a head-to-head contest judged by dermatologists!  As usual, we'll answer the questions you didn't know you had (well, maybe you knew you had some of these):
Is AI going to make our lives easier or is it going to replace us?
How good is AI at answering patient questions?
Will patients accept "AI Providers"?
How can you start levering AI now to make your life better?
What AI tools are out there to start using right now?
Are AI scribes all that great?

The Derms on Drugs give the definitive answer to the age old question:  What came first, the chicken or the egg?  You'll have to listen to find out.  

What's a Mazotti Reaction and why do you care?
How do JAK inhibitors compare to dupilumab for treating prurigo nodularis?
What's a cheap, easy, safe, effective treatment for palmoplantar pustulosis?
Can a steroid nasal spray help for Chronic Spontaneous Urticaria?
Do biologics reduce infection risk in AD more than JAK Inhibitors and why?
How does superficial radiation therapy compare to Mohs for skin cancer?
Dermal hyperpigmentation is impossible to treat - can isotretinoin help?
Cheilitis drives derms and patients nuts - what's the new, cheap, easy way to help?

Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why).
 
In this episode:
·       Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?
·       HS & spondyloarthritis: are you screening… should you be?
·       JAKs and the heart: are all cardiovascular risks created equal?
·       “2/3 HS remission” headlines: why this data shouldn’t change your practice
·       Tirbanibulin + cryo for AKs: combo win or marketing math?
·       Hydrochlorothiazide & skin cancer: do you really need that conversation?
·       Oral minoxidil + Olumiant: synergy or wishful thinking in AA?
·       OX40/OX40L blockers: exciting pathway—new hope or new hype?
 
Fast. Practical. Slightly skeptical (for good reason).

If you prescribe, counsel, or roll your eyes at bad data—this one’s for you.